Formulation and evaluation considerations of transdermal drug delivery system

International Journal of Pharmaceutical Research

Volumn 3, Issue 1, 2011, Pages 1-9

  Patel, Rakesh P ^a   Baria, Ashok H ^b  

^a GANPAT UNIVERSITY   (India)

^b Jodhpur National University   (India)

Author keywords

Patches; Penetration enhancer; Transdermal drug delivery systems (TDDS)

Indexed keywords

ADHESIVE AGENT; ATENOLOL; CAPTOPRIL; CARVEDILOL; CLONIDINE; DRUG CARRIER; ESTRADIOL; EXCIPIENT; GLYCERYL TRINITRATE; INDAPAMIDE; ISOSORBIDE DINITRATE; METOPROLOL; NICARDIPINE; NICOTINE; POLYMER; PROPRANOLOL; SCOPOLAMINE; TRANSDERM; UNCLASSIFIED DRUG; VERAPAMIL;

ARTICLE; DISPERSION; DOSE CALCULATION; DRUG DELIVERY SYSTEM; DRUG PENETRATION; DRUG SAFETY; DRUG TRANSPORT; HUMAN; IN VITRO STUDY; IN VIVO STUDY; NONHUMAN; PATENT; SHEAR STRENGTH; SKIN APPENDAGE; SKIN PENETRATION; SKIN STRUCTURE; STRATUM CORNEUM; SYSTEMIC THERAPY; TRANSCYTOSIS; TRANSDERMAL PATCH;

EID: 79954455546     PISSN: None     EISSN: 09752366     Source Type: Journal    
DOI: None     Document Type: Article

References (60)

1. Wokovich AM, Prodduturi S, Doub WH, Hussain AS and Buhse LF. Transdermal drug delivery system (TDDS) adhesion as a critical safety, efficacy and quality attribute. European Journal of Pharma. and Biopharm. 2006; 64:1-8.
2. Chowdary KP, Naidu RAS. Microencapsulation of solid dispersion of nifedipine. Indian Drugs 1995; 32 (9): 414-422.
3. Sridevi S and Krishna DR. Transdermal drug delivery systems. The Eastern Pharmacist 1991; 35: 17-24.
4. Ansel HC, Allen LV and Popovich NG. Pharmaceutical Dosage Forms and Drug Delivery systems. 7th ed. New York: Lippincott Williams & Wilkins; 2002.
5. Potts RO and Lobo RA. Transdermal drug delivery: clinical considerations for the obstetrician- gynecologist. Obstet Gynecol 2005; 105: 953-61.
6. Brown L and Langer R. Transdermal delivery of drugs. Ann Rev Med 1988; 39: 221-9.
7. Merkle HP. Transdermal delivery systems. Methods Find Exp Clin Pharmacol 1989; 11: 135-53.
8. Samisoe G. Transdermal hormone therapy: gels and patches. Climacteric 2004; 7:347-56.
9. Stevenson JC. Optimising delivery systems for HRT. Maturitas 1999; 33: S31-8.
10. Barry BW. Properties that Influence Percutaneous Absorption. 3rd ed. New York: Marcel Dekker, Inc.; 1983.
11. Guy RH, Hadgraft J and Bucks DAW. Transdermal drug delivery and cutaneous metabolism. Xenobiotica 1987; 17: 325-346.
12. Flynn GL. Percutaneous Absorption. 3rd ed. New York: Marcel Dekker Inc.; 1985.
13. Jacob SW and Francone CA. Structure and Function of Man. 2nd ed. Philadelphia: W.B. Saunders Co.; 1970.
14. Gros L and Clark WE. The structure of skin. In: Le G & Clark WE, editors. The tissue of the body, 6th ed. London: ELBS and Oxford University Press; 1980. p. 29-313.
15. Hadgraft J and Guy RH. Transdermal Drug Delivery. 2nd ed. New York: Marcel Dekker Inc.; 1989.
16. Chandrashekar NS and Shobharani RH. Physicochemical and Pharmacokinetic Parameters in drug selection and loading for transdermal drug delivery. Indian Journal of Pharmaceutical Sciences 2008; 70(1): 94-96.
17. Kumar TS, Selvam RP and Singh AK. Transdermal drug delivery systems for antihypertensive drugs. Int. J. Pharm. Biomed. Res. 2010; 1(1): 1-8.
18. Lee M, Phillips J. Transdermal patches: high risk for error? Drug Top 2002, 54-55.
19. Sugibayashi K and Morimoto Y. Polymers for transdermal drug delivery systems. Journal of Controlled Release 1994; 29: 177-185.
20. Ko CU. Effect of skin penetration enhancers in transdermal drug delivery adhesives on skin adhesion and irritation, Proceed. Intern. Symp. Control. Rel. Bioact. Mater 1996; 23: 281-282.
21. Qvist MH, Hoeck U, Kreilgaard B, Madsen F and Frokjaer S. Release of chemical penetration enhancers from drug-in-adhesive transdermal patches. Int. J. Pharm. 2002; 231: 253-263.
22. Barry BW. Lipid-protein-partititioning theory of skin penetration enhancement. J. Control. Release 1991; 15: 237- 248.
23. Williams AC and Barry BW. Penetration enhancers. Adv. Drug Delivery Reviews 2004; 56: 603- 618.
24. Minghetti P, Cilurzo F and Montanari L. Evaluation of adhesive properties of patches based on acrylic matrices. Drug Dev. Ind. Pharm. 1999; 25 (1):1-6.
25. Repka MA and McGinity JW. Bioadhesive properties of hydroxypropylcellulose topical films produced by hot-melt extrusion. J. Control. Release 2001; 70: 341-351.
26. Spencer TS, Smith SE and Conjeevaram S. Adhesive interactions between polymers and skin in transdermal delivery systems. Poly. Mater. Sci. Eng. 1990; 63: 337-339.
27. Minghetti P, Cilurzo F, Tosi L, Casiraghi A, and Montanari L. Design of a new water-soluble pressuresensitive adhesive for patch preparation. AAPS Pharm. Sci. Tech. 2003; 4 (1): -9.
28. Tyle P. Drug Delivery device. 3rd ed. New York and Basel: Marcel Dekker; 2003.
29. Wang C. Pharmacokinetics of transdermal Testosterone gel in hypogonadal men: application of gel at one site versus four sites: a general clinical research center study. J. Clin. Endocrinol. Metab. 2000; 85: 964-969.
30. Jarvinen A. Steady-state pharmacokinetics of oestradiol gel in post-menopausal women: effects of application area and washing. Br. J. Obstet. Gynaecol. 1997; 104(16): 14-18.
31. Lawrence CM. Site variation in anthralin inflammation on forearm skin. Br. J. Dermatol. 1986; 114: 609-613.
32. Harrison LL and Harari D. An evaluation of bioequivalence of two 7-day 17 beta-estradiol transdermal delivery systems by anatomical site. J. Clin. Pharmacol. 2002; 42: 1134-114.
33. Taggart W. The effect of site of application on the transcutaneous absorption of 17-beta estradiol from a transdermal delivery system (Climara). Menopause 2000; 7: 364-369.
34. Dupius D. In-vivo relationship between percutaneous absorption and transepidermal water loss according to anatomical site in man. J. Soc. Cosmet. Chem. 1986; 37: 351-357.
35. Roskos KV. The effect of aging on percutaneous adsorption in man. J. Pharmacokinet. Biopharm. 1989; 17: 617-630.
36. Maurice PD and Greaves MW. Relationship between skin type and erythemal response to anthralin. Br. J. Dermatol. 1983; 109: 337-341.
37. Reed JT. Skin type, but neither race nor gender, influences epidermal permeability barrier function. Arch. Dermatol. 1995; 131: 1134-1138.
38. Long CC and Marks R. Stratum corneum changes in patients with senile pruritis. J. Am. Acad. Dermatol. 1992; 27: 560-564
39. Allen A. Significant absorption of topical tacrolimus in 3 patients with Netherton syndrome. Arch. Dermatol. 2001; 137: 747-750.
40. Muizzuddin N. Impact of stress of marital dissolution on skin barrier recovery: tape stripping and measurement of transepidermal water loss (TEWL). Skin Res. Technol 2003; 9: 34-38.
41. Galer BS. Topical lidocaine patch relieves postherpetic neuralgia more effectively than a vehicle topical patch: results of an enrichment study. Pain 80 1999; 533-538.
42. Horning JR. Efficacy and safety of two-year therapy with transdermal clonidine for essential hypertension. Chest 93 1988: 941-945.
43. Peterson TA. Transdermal drug formulation and process development. Pharm. Tech. 2003; 27(6): 18-23.
44. Dias M, Farinha A, Faustino E, Hadgraft J, Pais J and Toscano C. Topical delivery of caffeine from some commercial formulations. Int. J. Pharmaceutics 1999; 182(1): 41-47.
45. Minghetti P, Cilurzo F and Montanari L. Evaluation of adhesive properties of patches based on acrylic matrices. Drug Dev. Ind. Pharm. 1999; 25 (1): 1-6.
46. Spencer TS, Smith SE and Conjeevaram S. Adhesive interactions between polymers and skin in transdermal delivery systems. Poly. Mater. Sci. Eng. 1990; 63: 337-339.
47. Peel SD. Handbook of Pressure Sensitive Adhesive Technology. 3rd ed. Rhode Island: Satas & Associates; 1999.
48. Steven-Fountain AJ, Atkins AG, Jeronimidis G, Vincent JFV, Farrar DF and Chivers RA. The effect of flexible substrates on pressure-sensitive adhesive performance. Int. J. Adhes. Adhes. 2002; 22: 423-430.
49. Satas D. Handbook of Pressure Sensitive Adhesive Technology. 3rd ed. Rhode Island: Satas & Associates; 1999.
50. Vollmer U and Cordes G. Physical quality control of transdermal delivery systems, Proceed. Int. Symp. Control. Rel. Bioact. Mater. 1997; 24: 685-686.
51. Chivers RA. Easy removal of pressure sensitive adhesives for skin applications. Int. J. Adhes. Adhes. 2001; 21: 381-388.
52. Steven-Fountain AJ, Atkins AG, Jeronimidis G, Vincent JFV, Farrar DF and Chivers RA. The effect of flexible substrates on pressure-sensitive adhesive performance. Int. J. Adhes. Adhes. 2002; 22: 423-430.
53. Fauth C, Wiedersberg S, Neubert RHH and Dittgen M. Adhesive backing foil interactions affecting the elasticity, adhesion strength of laminates, and how to interpret these properties of branded transdermal patches. Drug Dev. Ind. Pharm. 2002; 28(10): 1251-1259.
54. Satas D. Medical products. In: D. Satas, editor. Handbook of Pressure Sensitive Adhesive Technology, 3rd ed. Warwick, Rhode Island: Satas & Associates; 1999. p. 706.
55. Spencer TS, Smith SE and Conjeevaram S. Adhesive interactions between polymers and skin in transdermal delivery systems. Poly. Mater. Sci. Eng. 1990; 63: 337-339.
56. Rozenbaum H, Birkhäuser M, Nooyer CD, Lambotte R, Pornel B, Schneider H and Studd J. Comparison of two estradiol transdermal systems, tolerability, adhesion and efficacy. Maturitas 1996; 25: 161-173.
57. http://www.permegear.com [Cited 2010 July 28].
58. Fang JY, Sung KC, Lin HH, Fang CL. Transdermal iontophoretic delivery of diclofenac sodium from various polymer formulations: in-vitro and in-vivo studies. Int. J. Pharm. 1999; 178: 83-92.
59. Misra AN. Transdermal Drug Delivery. In: Jain NK, editor. Controlled and Novel drug delivery, New Delhi: CBS Publisher; 2002. p.110.
60. http://www.freepatentonline.com [Cited 2010 August 7].